November 24th 2024
Patients experienced similar safety and efficacy if they received first-line or later-line treatment for unresectable hepatocellular carcinoma (u-HCC).
Biologic Switching Patterns, Discontinuation in Psoriasis Investigated in New Study
June 22nd 2022An analysis of biologic drug use patterns in patients with psoriasis from Tuscany, Italy, associated etanercept with the highest frequency of switching to other biologics; secukinumab and ustekinumab were linked with the lowest risk.
Read More
Self-administration of Biologics Well Tolerated, Effective for Asthma and CRS With Nasal Polyps
June 22nd 2022The adequate safety and improved symptom burden observed with self-administration of biologic therapies at home for the management of severe asthma and chronic rhinosinusitis with nasal polyps suggests potential in shifting care away from the more costlier in-patient setting.
Read More
Generic Drug Savings Possibilities: $3.6 Billion to Medicare Using DTC Pricing
June 22nd 2022How much would have Medicare saved if it had the same ability to purchase generic drugs at the same price as individuals using direct-to-consumer (DTC) pharmacies like the Mark Cuban Cost Plus Drug Company? Billions, as it turns out.
Listen
Alignment Between Manufacturers, Payers Key to Improving Specialty Drug Affordability and Access
June 22nd 2022Panelists taking part in an AHIP 2022 session discuss collaborative strategies among payers, manufacturers, and policy makers to address challenges regarding affordability and access of novel disease modifying drugs entering the marketplace.
Read More
There Is More to Blame Than Tech for T1D Outcomes Disparities, Investigators Argue
June 21st 2022Investigators from the Pediatric Diabetes Center at Hassenfeld Children’s Hospital at NYU Langone investigated outcomes disparities as they related to diabetes technology use among youth living with type 1 diabetes (T1D).
Read More
Dr Debra Patt: Telemedicine’s Contribution to Cancer Care Robust and Meaningful
June 20th 2022Debra Patt, MD, PhD, MBA, executive vice president of Texas Oncology, discusses how enhancements to telemedicine precipitated by the COVID-19 pandemic have made lasting and meaningful changes to oncology care, including that these care improvements will persist post pandemic.
Watch
Major Adverse Cardiac Events Related to ICI Treatment Explored in New Study
June 17th 2022Major adverse cardiac events are rare but serious in patients treated with immune checkpoint inhibitors (ICIs), and increased awareness is crucial to identify and treat these conditions in a timely manner.
Read More
Caregiver Contributions in Heart Failure Require Further Study
June 16th 2022The primary outcomes of this secondary analysis of the MOTIVATE-HF study were improvement in caregiver self-efficacy while caring for patients living with heart failure and caregiver contributions to self-care for these patients following motivational interviewing.
Read More
Dr Elaine Siegfried Addresses Patient-Centered Therapeutic Management for Atopic Dermatitis
June 16th 2022Elaine Siegfried, MD, professor of pediatrics and dermatology, Saint Louis University Health Sciences Center, discusses therapeutic management considerations for dermatologists in consulting with diverse patients with atopic dermatitis.
Watch
Nasal Polyps in CRS Found to Influence Risk of Past, Current Proton Pump Inhibitor Use
June 16th 2022Incidence of chronic rhinosinusitis (CRS) was associated with a higher rate of current and past proton pump inhibitor (PPI) use, in which elevated risk of PPI use and prescription duration were only found in those with CRS who did not have nasal polyps.
Read More
Dr Mazyar Shadman Highlights the Challenges of Subgroup Analysis When Trials Lack Diversity
June 16th 2022Increased diversity in clinical trials remains an unmet need, and in the new SEQUOIA trial, the majority of patients being White males meant researchers could not do a subgroup analysis looking at outcomes for specific races, age groups or genders, said Mazyar Shadman, MD, MPH, of Fred Hutchinson Cancer Research Center.
Watch
Symptom Burden, QOL in CRSwNP Significantly Improved With Novel Fluticasone Delivery System
June 14th 2022Patients with chronic rhinosinusitis with nasal polyps (CRSwNP) who are surgery-naive or whose symptoms recur after endoscopic sinus surgery exhibited similarly significant benefits in quality of life (QOL) and symptom burden when given an exhalation system with fluticasone.
Read More
The FDA determined that the 3-dose Pfizer COVID-19 vaccine worked in children aged 6 months through 4 years; the bipartisan Senate gun deal will focuses on mental health; the pandemic has other viruses acting mysteriously, with children diagnosed with respiratory viruses in May and June.
Read More